Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Ahn, D. [1 ]
Park, N. J. [2 ]
Locker, M. C. [2 ]
Zhou, Z-Y. [3 ]
Nie, X. [3 ]
Wang, T. [3 ]
Yu, S. [2 ]
机构：
[1] Mayo Clin, Dept Med Oncol, Phoenix, AZ USA
[2] Exelixis Inc, Dept Med Affairs, Alameda, CA USA
[3] Anal Grp Inc, Dept Healthcare, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2144
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1000P
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [21] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Abraham, Pranav
    Gricar, Joe
    Zhang, Ying
    Shankaran, Veena
    ADVANCES IN THERAPY, 2020, 37 (07) : 3392 - 3403
  • [22] Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes
    Venugopal, Balaji
    Pillai, Manon
    Powles, Thomas
    Savage, Philip
    Michael, Agnieszka
    Fife, Kate
    Klair, Bhupinder
    Perrot, Valerie
    Szabados, Bernadett
    CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 94 - +
  • [23] Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
    Xavier Adhoute
    Marie De Matharel
    Laurent Mineur
    Guillaume Pénaranda
    Dann Ouizeman
    Clemence Toullec
    Albert Tran
    Paul Castellani
    Armelle Rollet
    Valérie Oules
    Hervé Perrier
    Si Nafa Si Ahmed
    Marc Bourliere
    Rodolphe Anty
    World Journal of Gastrointestinal Oncology, 2022, (08) : 1510 - 1527
  • [24] Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
    Adhoute, Xavier
    De Matharel, Marie
    Mineur, Laurent
    Penaranda, Guillaume
    Ouizeman, Dann
    Toullec, Clemence
    Tran, Albert
    Castellani, Paul
    Rollet, Armelle
    Oules, Valerie
    Perrier, Herve
    Ahmed, Si Nafa Si
    Bourliere, Marc
    Anty, Rodolphe
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (08) : 1510 - 1527
  • [25] Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab
    Fung, Andrea S.
    Tam, Vincent C.
    Meyers, Daniel E.
    Sim, Hao-Wen
    Knox, Jennifer J.
    Zaborska, Valeriya
    Davies, Janine
    Ko, Yoo-Joung
    Batuyong, Eugene
    Samawi, Haider
    Cheung, Winson Y.
    Lee-Ying, Richard
    CANCER MEDICINE, 2020, 9 (13): : 4640 - 4647
  • [26] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    CANCER MEDICINE, 2024, 13 (09):
  • [27] Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study
    Lu, J.
    Zhu, H.
    Guo, J.
    Teng, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S671 - S671
  • [28] A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)
    Qi, Qi
    Liu, Yang
    Li, Rentao
    Liu, Yayue
    Zhang, Xihao
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Personeni, Nicola
    Pressiani, Tiziana
    Bozzarelli, Silvia
    Rimassa, Lorenza
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (10) : 788 - 803
  • [30] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Nicola Personeni
    Tiziana Pressiani
    Silvia Bozzarelli
    Lorenza Rimassa
    World Journal of Gastrointestinal Oncology, 2019, (10) : 788 - 803
12345